2026-W46 · Nov 9–Nov 15 · Company · Profile · published
Biogen company profile · biotechnology (multiple sclerosis, Alzheimer's, rare diseases) · history · financial snapshot · S&P 500 rank #282 · 百健公司業務歷史財務與標普500地位
SNAPSHOT
| Ticker | BIIB (NASDAQ) |
| Company | Biogen Inc. |
| GICS sector / industry | Health Care (XLV) / Biotechnology |
| S&P 500 rank (by weight) | #282 · 0.05% (Oct 30, 2026) |
| Sector rank (by market cap) | #35 in Health Care (Oct 30, 2026) |
| Share price (frozen benchmark) | $253.62 (Oct 30, 2026) |
| Headquarters | Cambridge, Massachusetts |
| Founded | 1978 (in Geneva, by Charles Weissmann and others; moved to Cambridge) |
| CEO | Christopher A. Viehbacher (President and CEO) |
| Employees | about 7,000 (2026 profile) |
| Market cap | $37.49B (Oct 30, 2026) |
WHAT IT DOES
Biogen is a biotechnology company focused on neuroscience: multiple sclerosis therapies (including Tysabri and Tecfidera), the Alzheimer's drug Leqembi (co-developed with Eisai), spinal muscular atrophy treatment Spinraza, and a pipeline in rare diseases and immunology. It also earns royalties and contract manufacturing revenue.
The model is patent-protected biologics: high prices on small patient populations fund long research cycles, and biosimilar competition erodes older franchises. FY2025 total revenue was $9.891B, up 2.2% from $9.676B, operating income was $1.86B (one data provider reports $1.88B on a different line basis — $1.86B is used here), net income was $1.293B, GAAP diluted EPS was $8.79 and non-GAAP diluted EPS was $15.28.
Leqembi is the swing factor: Alzheimer's uptake has been slower than hoped, and the drug's commercial trajectory decides whether the pipeline story holds.
BUSINESS SEGMENTS — FY2025
| Segment | Revenue | Share | YoY |
|---|---|---|---|
| Multiple sclerosis | — | — | — |
| Alzheimer's (Leqembi) | — | — | — |
| Rare diseases and other | — | — | — |
HISTORY
| Year | Milestone |
|---|---|
| 1978 | Founded in Geneva by Charles Weissmann and others as Biogen |
| 1986 | First interferon product approved; the company moves to Cambridge, Massachusetts |
| 1996 | Avonex approved for multiple sclerosis |
| 2021 | Aduhelm approved for Alzheimer's, then commercially withdrawn |
| 2025 | FY2025 total revenue reaches $9.891B, with net income of $1.293B; Leqembi rollout continues |
COMPETITIVE POSITION
FINANCIAL SNAPSHOT — FY2025
| Total revenue | $9.891B (+2.2% YoY) |
| Operating income | $1.86B |
| Net income | $1.293B |
| GAAP diluted EPS / Non-GAAP diluted EPS | $8.79 / $15.28 |
KEY RISKS
WHY IT MATTERS FOR THE S&P 500
Biogen is the S&P 500's neuroscience biotech: at a 0.05% index weight and #35 in Health Care by market cap, it is the index's main exposure to Alzheimer's and multiple sclerosis drug development.
Its Leqembi uptake and pipeline readouts are a standing read on neurology — Alzheimer's commercialization moves before broader biotech data does.
SOURCES & METHODOLOGY
| Market data | Slickcharts S&P 500 by weight (rank, weight, price — Oct 30, 2026 close) and Slickcharts S&P 500 analysis page (market cap) |
| Financials | Biogen FY2025 results (fiscal year ended Dec 31, 2025), company profile sources |
| Sector classification | GICS (Biotechnology) via the List of S&P 500 companies (Wikipedia) |
| Library data | SPXSet logo library, compiled from company official websites, filings, or Wikipedia; as company logos are dynamic corporate information, no 100% guarantee is made for the graphics. SPXSet chart library, monthly bars, compiled from Yahoo public information. |
Source: Yahoo Finance monthly bars, split-adjusted · Data as of Sep 30, 2026 (last closed month) · SPXSet.com
FINANCIALS
公司快照
| 代碼 | BIIB(NASDAQ) |
| 公司 | Biogen Inc. |
| GICS 板塊/行業 | 醫療保健(XLV)/生物科技 |
| 標普500排名(按權重) | #282 · 0.05%(2026 年 10 月 30 日) |
| 板塊內排名(按市值) | 醫療保健第 #35(2026 年 10 月 30 日) |
| 股價(凍結基準) | $253.62(2026 年 10 月 30 日) |
| 總部 | 美國麻省劍橋 |
| 成立 | 1978 年(日內瓦,Charles Weissmann 等人創辦;後遷劍橋) |
| 行政總裁 | Christopher A. Viehbacher(總裁兼行政總裁) |
| 員工 | 約 7,000(2026 年簡介) |
| 市值 | $37.49B(2026 年 10 月 30 日) |
業務概覽
百健是專注神經科學的生物科技公司:多發性硬化症療法(包括 Tysabri 與 Tecfidera)、阿爾茨海默病藥物 Leqembi(與衛材共同開發)、脊髓性肌萎縮症治療 Spinraza,以及罕見病與免疫學管線;另賺取專利費與合約生產收入。
其模式為專利保護的生物製劑:小患者群體的高定價資助漫長的研究週期,生物類似藥競爭侵蝕舊有特許經營。FY2025 總收入為 $9.891B,同比增長 2.2%(FY2024 為 $9.676B),營業利潤為 $1.86B(一家數據商按不同口徑報 $1.88B——本篇用 $1.86B),淨利潤為 $1.293B,GAAP 攤薄每股收益為 $8.79,非 GAAP 攤薄每股收益為 $15.28。
Leqembi 是波動因素:阿爾茨海默病用藥推廣慢於預期,其商業軌跡決定管線故事是否成立。
業務板塊 — FY2025
| 板塊 | 收入 | 佔比 | 同比 |
|---|---|---|---|
| 多發性硬化症 | — | — | — |
| 阿爾茨海默病(Leqembi) | — | — | — |
| 罕見病及其他 | — | — | — |
歷史沿革
| 年份 | 里程碑 |
|---|---|
| 1978 | 在日內瓦創立,由 Charles Weissmann 等人創辦,名為 Biogen |
| 1986 | 首個干擾素產品獲批;公司遷往麻省劍橋 |
| 1996 | Avonex 獲批用於多發性硬化症 |
| 2021 | Aduhelm 獲批用於阿爾茨海默病,後商業撤回 |
| 2025 | FY2025 總收入達 $9.891B,淨利潤為 $1.293B;Leqembi 繼續推廣 |
競爭地位
財務快照 — FY2025
| 總收入 | $9.891B(同比 +2.2%) |
| 營業利潤 | $1.86B |
| 淨利潤 | $1.293B |
| GAAP 攤薄每股收益/非 GAAP 攤薄每股收益 | $8.79/$15.28 |
主要風險
對標普500的重要性
百健是標普500的神經科學生物科技標的:指數權重 0.05%、醫療保健板塊市值第 #35,是指數對阿爾茨海默病與多發性硬化症藥物開發的主要敞口。
其 Leqembi 採用與管線結果,是神經學的常設讀數——阿爾茨海默病商業化往往先於更廣泛的生物科技數據變動。
來源與方法
| 市場數據 | Slickcharts 標普500權重榜(排名、權重、價格——2026 年 10 月 30 日收盤)及 Slickcharts 標普500分析頁(市值) |
| 財務 | 百健 FY2025 業績(財政年度截至 2025 年 12 月 31 日)、公司簡介來源 |
| 板塊分類 | GICS(生物科技),據 S&P 500 公司清單(Wikipedia) |
| 圖庫數據 | SPXSet logo 庫,整理自企業官方網站、文件或維基百科;由於是企業自身動態資訊,不對圖形做百分百保證。 SPXSet 圖表庫月線,整理自 Yahoo 公開資訊。 |
來源:Yahoo Finance 月 K(經拆股調整)· 數據截至 2026 年 9 月 30 日(最後已收月份) · SPXSet.com
財報
SPXSet in-house research — market structure, options and volatility. Not investment advice.
SPXSet 站內獨立研究,聚焦 SPX 市場結構、期權與波動率;內容不構成投資建議。
Entered 2026-11-01 20:32 · updated 2026-11-14 23:02 · rev 5